Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study.
ODM-209 showed activity in heavily pretreated participants with mCRPC, particularly those with activating AR-LBD mutations, with an expected AE profile.